Analysis and Commentary 7/18/20 Analysis and Commentary 7/18/20 Why No Movement in the Senate? Read More Analysis and Commentary 7/10/20 Analysis and Commentary 7/10/20 CBER Director on COVID-19 and Vaccine Development Read More Analysis and Commentary 6/26/20 Analysis and Commentary 6/26/20 FDA Is Its People … and They Need Our Support (Redux) Read More Analysis and Commentary 6/19/20 Analysis and Commentary 6/19/20 How Well Is This Year's Appropriation Process Working? Read More Analysis and Commentary 6/12/20 Analysis and Commentary 6/12/20 "I Believe in FDA Exceptionalism and You Should Too" Read More Analysis and Commentary 6/5/20 Analysis and Commentary 6/5/20 Pandemic Actions Taken ... and Lessons Learned Read More Analysis and Commentary 5/15/20 Analysis and Commentary 5/15/20 How H.R. 6800 Might Impact the FDA Read More Analysis and Commentary 5/8/20 Analysis and Commentary 5/8/20 The Frieden Health Defense Funding Proposition Read More Analysis and Commentary 5/1/20 Analysis and Commentary 5/1/20 No Need for a Crystal Ball in Some Scenarios Read More Analysis and Commentary 4/24/20 Analysis and Commentary 4/24/20 How Can Congress Agree to Appropriations for FY 21? Read More Analysis and Commentary 4/17/20 Analysis and Commentary 4/17/20 The COVID-19 Pandemic and Maintenance of a Continued Safe Food Supply Read More Analysis and Commentary 4/3/20 Analysis and Commentary 4/3/20 Advocating for a Responsibility-based "Ask" Read More Analysis and Commentary 3/27/20 Analysis and Commentary 3/27/20 Coronavirus, Pandemic Preparedness, and Beyond Read More Analysis and Commentary 3/19/20 Analysis and Commentary 3/19/20 Alliance for a Stronger FDA -- FY 21 “Ask” and Explanation Read More Analysis and Commentary 3/13/20 Analysis and Commentary 3/13/20 "Cures," Coronavirus, NDD, and Other Issues for FY 21 Read More Analysis and Commentary 3/5/20 Analysis and Commentary 3/5/20 Additional funding for FDA; more Qs and As Read More Analysis and Commentary 2/27/20 Analysis and Commentary 2/27/20 More Qs and As About the FY 21 Appropriation Process Read More Analysis and Commentary 2/21/20 Analysis and Commentary 2/21/20 TMAP: Planning for Efficient, Effective Data Management at FDA Read More Analysis and Commentary 2/14/20 Analysis and Commentary 2/14/20 The Alliance's Assessment of the President's FY 21 Budget Request Read More Analysis and Commentary 2/7/20 Analysis and Commentary 2/7/20 Shuren Fills Alliance in on Fast-Moving Science and CDRH Needs Read More Newer Posts Older Posts
Analysis and Commentary 7/18/20 Analysis and Commentary 7/18/20 Why No Movement in the Senate? Read More
Analysis and Commentary 7/10/20 Analysis and Commentary 7/10/20 CBER Director on COVID-19 and Vaccine Development Read More
Analysis and Commentary 6/26/20 Analysis and Commentary 6/26/20 FDA Is Its People … and They Need Our Support (Redux) Read More
Analysis and Commentary 6/19/20 Analysis and Commentary 6/19/20 How Well Is This Year's Appropriation Process Working? Read More
Analysis and Commentary 6/12/20 Analysis and Commentary 6/12/20 "I Believe in FDA Exceptionalism and You Should Too" Read More
Analysis and Commentary 6/5/20 Analysis and Commentary 6/5/20 Pandemic Actions Taken ... and Lessons Learned Read More
Analysis and Commentary 5/15/20 Analysis and Commentary 5/15/20 How H.R. 6800 Might Impact the FDA Read More
Analysis and Commentary 5/8/20 Analysis and Commentary 5/8/20 The Frieden Health Defense Funding Proposition Read More
Analysis and Commentary 5/1/20 Analysis and Commentary 5/1/20 No Need for a Crystal Ball in Some Scenarios Read More
Analysis and Commentary 4/24/20 Analysis and Commentary 4/24/20 How Can Congress Agree to Appropriations for FY 21? Read More
Analysis and Commentary 4/17/20 Analysis and Commentary 4/17/20 The COVID-19 Pandemic and Maintenance of a Continued Safe Food Supply Read More
Analysis and Commentary 4/3/20 Analysis and Commentary 4/3/20 Advocating for a Responsibility-based "Ask" Read More
Analysis and Commentary 3/27/20 Analysis and Commentary 3/27/20 Coronavirus, Pandemic Preparedness, and Beyond Read More
Analysis and Commentary 3/19/20 Analysis and Commentary 3/19/20 Alliance for a Stronger FDA -- FY 21 “Ask” and Explanation Read More
Analysis and Commentary 3/13/20 Analysis and Commentary 3/13/20 "Cures," Coronavirus, NDD, and Other Issues for FY 21 Read More
Analysis and Commentary 3/5/20 Analysis and Commentary 3/5/20 Additional funding for FDA; more Qs and As Read More
Analysis and Commentary 2/27/20 Analysis and Commentary 2/27/20 More Qs and As About the FY 21 Appropriation Process Read More
Analysis and Commentary 2/21/20 Analysis and Commentary 2/21/20 TMAP: Planning for Efficient, Effective Data Management at FDA Read More
Analysis and Commentary 2/14/20 Analysis and Commentary 2/14/20 The Alliance's Assessment of the President's FY 21 Budget Request Read More
Analysis and Commentary 2/7/20 Analysis and Commentary 2/7/20 Shuren Fills Alliance in on Fast-Moving Science and CDRH Needs Read More
